A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Public ClinicalTrials.gov record NCT05780034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Malignancy Activity of AC676 in Patients With Relapsed/Refractory B-cell Malignancies
Study identification
- NCT ID
- NCT05780034
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Accutar Biotechnology Inc
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- AC676 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 19, 2023
- Primary completion
- Mar 30, 2026
- Completion
- May 30, 2026
- Last update posted
- Oct 1, 2025
2023 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| The Ohio State University - The James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210 | Recruiting |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37302 | Withdrawn |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | Recruiting |
| Swedish Cancer Institute | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05780034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05780034 live on ClinicalTrials.gov.